UA113013C2 - ПІПЕРАЗИНО[1,2-а]ІНДОЛ-1-ОНИ ТА [1,4]ДІАЗЕПІНО[1,2-а]ІНДОЛ-1-ОН - Google Patents
ПІПЕРАЗИНО[1,2-а]ІНДОЛ-1-ОНИ ТА [1,4]ДІАЗЕПІНО[1,2-а]ІНДОЛ-1-ОНInfo
- Publication number
- UA113013C2 UA113013C2 UAA201501071A UAA201501071A UA113013C2 UA 113013 C2 UA113013 C2 UA 113013C2 UA A201501071 A UAA201501071 A UA A201501071A UA A201501071 A UAA201501071 A UA A201501071A UA 113013 C2 UA113013 C2 UA 113013C2
- Authority
- UA
- Ukraine
- Prior art keywords
- lower alkyl
- halogen
- substituted
- disease
- hydrogen
- Prior art date
Links
- CVCSXBCKBNWYAB-UHFFFAOYSA-N [1,4]diazepino[1,2-a]indol-1-one Chemical compound O=C1N=CC=CN2C3=CC=CC=C3C=C12 CVCSXBCKBNWYAB-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical group 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- -1 benzo[1,3]dioxolyl,2,3-dihydro-benzofuran-5-yl Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102000014461 Ataxins Human genes 0.000 abstract 1
- 108010078286 Ataxins Proteins 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010008025 Cerebellar ataxia Diseases 0.000 abstract 1
- 208000027104 Chemotherapy-Related Cognitive Impairment Diseases 0.000 abstract 1
- 206010011878 Deafness Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000007737 Retinal degeneration Diseases 0.000 abstract 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000009205 Tinnitus Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 abstract 1
- 230000037326 chronic stress Effects 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000010370 hearing loss Effects 0.000 abstract 1
- 231100000888 hearing loss Toxicity 0.000 abstract 1
- 208000016354 hearing loss disease Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 229960001252 methamphetamine Drugs 0.000 abstract 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 abstract 1
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 abstract 1
- 229950010883 phencyclidine Drugs 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 230000004258 retinal degeneration Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 231100000886 tinnitus Toxicity 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12179381 | 2012-08-06 | ||
| PCT/EP2013/066344 WO2014023674A1 (en) | 2012-08-06 | 2013-08-05 | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA113013C2 true UA113013C2 (uk) | 2016-11-25 |
Family
ID=48918402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201501071A UA113013C2 (uk) | 2012-08-06 | 2013-08-05 | ПІПЕРАЗИНО[1,2-а]ІНДОЛ-1-ОНИ ТА [1,4]ДІАЗЕПІНО[1,2-а]ІНДОЛ-1-ОН |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9284321B2 (enExample) |
| EP (1) | EP2880036B1 (enExample) |
| JP (1) | JP5974177B2 (enExample) |
| KR (1) | KR101716062B1 (enExample) |
| CN (1) | CN104540829B (enExample) |
| AR (1) | AR092041A1 (enExample) |
| AU (1) | AU2013301577B2 (enExample) |
| BR (1) | BR112015000313A2 (enExample) |
| CA (1) | CA2880682A1 (enExample) |
| CL (1) | CL2015000143A1 (enExample) |
| CO (1) | CO7141435A2 (enExample) |
| CR (1) | CR20140545A (enExample) |
| EA (1) | EA025884B1 (enExample) |
| IL (1) | IL236808B (enExample) |
| MA (1) | MA37791B1 (enExample) |
| MX (1) | MX362184B (enExample) |
| MY (1) | MY185216A (enExample) |
| NZ (1) | NZ703192A (enExample) |
| PE (1) | PE20150341A1 (enExample) |
| PH (1) | PH12015500059B1 (enExample) |
| SG (1) | SG11201408529VA (enExample) |
| TW (1) | TWI506027B (enExample) |
| UA (1) | UA113013C2 (enExample) |
| WO (1) | WO2014023674A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2913335T3 (es) * | 2013-02-18 | 2022-06-01 | Labrador Diagnostics Llc | Análisis de imagen y medición de muestras biológicas |
| MX2015013915A (es) * | 2013-04-02 | 2015-12-11 | Hoffmann La Roche | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona. |
| RU2673489C2 (ru) * | 2013-09-12 | 2018-11-27 | Ф. Хоффманн-Ля Рош Аг | Производные индолкарбоксамида |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1965981C3 (de) * | 1968-02-13 | 1978-08-31 | Sumitomo Chemical Co., Ltd., Osaka (Japan) | 9-Phenyl-lO-oxopiperazino [l,2-a]-indole und Verfahren zu ihrer Herstellung |
| GB0106177D0 (en) * | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| GB0202015D0 (en) * | 2002-01-29 | 2002-03-13 | Hoffmann La Roche | Piperazine Derivatives |
| ATE448230T1 (de) * | 2005-12-09 | 2009-11-15 | Hoffmann La Roche | Für die behandlung von obesitas geeignete tricyclische amidderivate |
| WO2008046072A2 (en) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Chemical inducers of neurogenesis |
| MX2009004898A (es) * | 2006-11-09 | 2009-05-19 | Hoffmann La Roche | Derivados de indol y de benzofurano-2-carboxamida. |
| CA2804161A1 (en) | 2010-07-07 | 2012-01-12 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| MX2015013915A (es) * | 2013-04-02 | 2015-12-11 | Hoffmann La Roche | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona. |
-
2013
- 2013-08-05 MY MYPI2014003519A patent/MY185216A/en unknown
- 2013-08-05 JP JP2015525846A patent/JP5974177B2/ja not_active Expired - Fee Related
- 2013-08-05 WO PCT/EP2013/066344 patent/WO2014023674A1/en not_active Ceased
- 2013-08-05 PE PE2015000024A patent/PE20150341A1/es active IP Right Grant
- 2013-08-05 BR BR112015000313A patent/BR112015000313A2/pt not_active Application Discontinuation
- 2013-08-05 SG SG11201408529VA patent/SG11201408529VA/en unknown
- 2013-08-05 KR KR1020157003112A patent/KR101716062B1/ko not_active Expired - Fee Related
- 2013-08-05 UA UAA201501071A patent/UA113013C2/uk unknown
- 2013-08-05 AR ARP130102771A patent/AR092041A1/es unknown
- 2013-08-05 TW TW102128001A patent/TWI506027B/zh not_active IP Right Cessation
- 2013-08-05 EP EP13745648.9A patent/EP2880036B1/en active Active
- 2013-08-05 MX MX2015001318A patent/MX362184B/es active IP Right Grant
- 2013-08-05 CA CA2880682A patent/CA2880682A1/en not_active Abandoned
- 2013-08-05 AU AU2013301577A patent/AU2013301577B2/en not_active Ceased
- 2013-08-05 NZ NZ703192A patent/NZ703192A/en not_active IP Right Cessation
- 2013-08-05 CN CN201380041546.5A patent/CN104540829B/zh not_active Expired - Fee Related
- 2013-08-05 EA EA201590125A patent/EA025884B1/ru not_active IP Right Cessation
-
2014
- 2014-11-27 CR CR20140545A patent/CR20140545A/es unknown
- 2014-11-28 CO CO14262433A patent/CO7141435A2/es unknown
-
2015
- 2015-01-09 PH PH12015500059A patent/PH12015500059B1/en unknown
- 2015-01-19 IL IL236808A patent/IL236808B/en not_active IP Right Cessation
- 2015-01-20 MA MA37791A patent/MA37791B1/fr unknown
- 2015-01-21 CL CL2015000143A patent/CL2015000143A1/es unknown
- 2015-02-04 US US14/614,232 patent/US9284321B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016008842A (es) | Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos. | |
| MX2016000895A (es) | Derivados de 1,7-naftiridina. | |
| MX2015006364A (es) | 1,6-naftiridinas sustituidas. | |
| BR112015004942A2 (pt) | benzimidazóis como agentes ativos do snc | |
| MX2015015052A (es) | Derivados de isoquinolina que estimulan la neurogenesis. | |
| AR093576A1 (es) | Derivados heterociclicos sustituidos | |
| MX375169B (es) | Derivados de indolin-2-ona o pirrolo-piridin-2-ona. | |
| MX381925B (es) | Peliculas termocontraibles de barrera de multicapa pvdc. | |
| MX2016008536A (es) | Derivados de fluoro-naftilo. | |
| PH12016500605A1 (en) | Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders | |
| PH12015500059B1 (en) | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one | |
| BR112015008200A2 (pt) | derivados de imidazopiridina | |
| MX363461B (es) | Derivados de benzisoxazol como moduladores de la neurogénesis y el uso de los mismos en el tratamiento de enfermedades neurológicas y trastornos neuropsiquiátricos. | |
| MX2015013915A (es) | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona. | |
| MX2016001528A (es) | Derivados de indol-carboxamida. | |
| TH165816A (th) | ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท | |
| PH12013501724A1 (en) | Glycine transporter-inhibiting substances |